Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
canfosfamide + carboplatin
- Development stage
- Unknown
- Lead developer
- Telik
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Canfosfamide + carboplatin is a combination regimen investigated primarily in oncology. Canfosfamide (also known as TLK286, Telcyta) is a glutathione analog prodrug activated by glutathione S-transferase P1-1, an enzyme often over-expressed in various tumors. Once activated, canfosfamide generates cytotoxic moieties that induce apoptosis in cancer cells. Carboplatin is a platinum-based chemotherapeutic that forms DNA crosslinks, leading to apoptosis. This combination was studied especially in platinum-resistant or platinum-refractory ovarian cancer and in non-small cell lung cancer (NSCLC). The combination did not show survival benefits in phase 3 ovarian cancer trials, but demonstrated activity and acceptable safety in early phase NSCLC studies[1][2][3][4].
- Brand names
- ParaplatinParaplatin Novaplus
- Other names
- canfosfamide + carboplatin
02
Targets
DNAGSTP1 (Glutathione S-transferase P)
Beyond the preview
Go deeper on canfosfamide + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on canfosfamide + carboplatin.